What do systematic reviews say?

Intratympanic corticosteroids vs placebo/no treatment

It is very uncertain whether intratympanic corticosteroids changes serious adverse events compared with placebo/no treatment (very low certainty).

• Intratympanic corticosteroids for Ménière’s disease 2023 · Cochrane Headline outcomes only
  RR 0.64 [0.22, 1.85]
  4 studies · 500 participants
  Very low

Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant vs no intervention

• Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 18 participants
  Very low

Anti‐IL‐5 mAb (mepolizumab) vs placebo (on top of topical steroids)

It is very uncertain whether anti‐IL‐5 mAb (mepolizumab) changes serious adverse events compared with placebo (on top of topical steroids) (very low certainty).

• Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
  RR 1.57 [0.07, 35.46]
  2 studies · 135 participants
  Very low

Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)

It is very uncertain whether anti‐IgE mAb (omalizumab) changes serious adverse events compared with placebo (on top of topical steroids) (very low certainty).

• Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
  RR 0.32 [0.05, 2]
  5 studies · 329 participants
  Very low

Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)

Anti‐IL‐4Rα mAb (dupilumab) may leads to lower serious adverse events compared with placebo (on top of topical steroids) (low certainty).

• Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
  RR 0.47 [0.29, 0.76]
  3 studies · 782 participants
  Low